Literature DB >> 18728388

Expanding role of cyclin dependent kinases in cytokine inducible gene expression.

Allan R Brasier1.   

Abstract

The Positive Transcriptional Elongation Factor b (P-TEFb), a heterodimer of CDK9 and Cyclin T1, is widely implicated in control of basal gene expression. Here, P-TEFb is involved in transitioning paused RNA polymerase II to enter productive transcriptional elongation mode by phosphorylating negative elongation factors and Ser(2) of the heptad repeat in the RNA Pol II COOH terminal domain (CTD). This perspective will examine recent work in two unrelated inducible signaling pathways that illustrate the central role of P-TEFb in mediating cytokine inducible transcription networks. Specifically, P-TEFb has been recently discovered to play a key role in TNF-inducible NFkappaB activation and IL-6-inducible STAT3 signaling. In these signaling cascades, P-TEFb forms protein complexes with the activated nuclear RelA and STAT3 transcription factor in the cellular nucleoplasm, an association important for P-TEFb's promoter targeting. Studies using siRNA-mediated knockdown and/or selective CDK inhibitors show that P-TEFb plays a functional role in activation of a subset of NFkappaB-dependent targets and all STAT3-dependent genes studied to date. Interestingly, cytokine inducible genes that are sensitive to P-TEFb inhibition share an induction mechanism requiring inducible RNA Pol II recruitment. Chromatin immunoprecipitation studies have preliminarily indicated that this recruitment is dependent on CDK enzymatic activity. The potential of inhibiting P-TEFb as an anti-inflammatory therapy in innate immunity and systemic inflammation will be discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18728388      PMCID: PMC3019574          DOI: 10.4161/cc.7.17.6594

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  60 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK.

Authors:  J D Woronicz; X Gao; Z Cao; M Rothe; D V Goeddel
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

3.  IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.

Authors:  F Mercurio; H Zhu; B W Murray; A Shevchenko; B L Bennett; J Li; D B Young; M Barbosa; M Mann; A Manning; A Rao
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

4.  A fourth IkappaB protein within the NF-kappaB signaling module.

Authors:  Soumen Basak; Hana Kim; Jeffrey D Kearns; Vinay Tergaonkar; Ellen O'Dea; Shannon L Werner; Chris A Benedict; Carl F Ware; Gourisankar Ghosh; Inder M Verma; Alexander Hoffmann
Journal:  Cell       Date:  2007-01-26       Impact factor: 41.582

5.  Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300.

Authors:  A E Horvai; L Xu; E Korzus; G Brard; D Kalafus; T M Mullen; D W Rose; M G Rosenfeld; C K Glass
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 6.  Transcription elongation and eukaryotic gene regulation.

Authors:  C A Spencer; M Groudine
Journal:  Oncogene       Date:  1990-06       Impact factor: 9.867

7.  Respiratory syncytial virus influences NF-kappaB-dependent gene expression through a novel pathway involving MAP3K14/NIK expression and nuclear complex formation with NF-kappaB2.

Authors:  Sanjeev Choudhary; Steve Boldogh; Roberto Garofalo; Mohammad Jamaluddin; Allan R Brasier
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway.

Authors:  Giichi Takaesu; Rama M Surabhi; Kyu-Jin Park; Jun Ninomiya-Tsuji; Kunihiro Matsumoto; Richard B Gaynor
Journal:  J Mol Biol       Date:  2003-02-07       Impact factor: 5.469

9.  Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.

Authors:  Martin J Boulanger; Dar-chone Chow; Elena E Brevnova; K Christopher Garcia
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

10.  Roles of IL-6-gp130 Signaling in Vascular Inflammation.

Authors:  Tieying Hou; Brian C Tieu; Sutapa Ray; Adrian Recinos Iii; Ruwen Cui; Ronald G Tilton; Allan R Brasier
Journal:  Curr Cardiol Rev       Date:  2008-08
View more
  19 in total

1.  Oct-1 cooperates with the TATA binding initiation complex to control rapid transcription of human iNOS.

Authors:  Sylvie Reveneau; Thodoris G Petrakis; Christopher E Goldring; Aurélie Chantôme; Jean-François Jeannin; Alena Pance
Journal:  Cell Mol Life Sci       Date:  2012-02-19       Impact factor: 9.261

2.  CTIP2 is a negative regulator of P-TEFb.

Authors:  Thomas Cherrier; Valentin Le Douce; Sebastian Eilebrecht; Raphael Riclet; Céline Marban; Franck Dequiedt; Yannick Goumon; Jean-Christophe Paillart; Mathias Mericskay; Ara Parlakian; Pedro Bausero; Wasim Abbas; Georges Herbein; Siavash K Kurdistani; Xavier Grana; Benoit Van Driessche; Christian Schwartz; Ermanno Candolfi; Arndt G Benecke; Carine Van Lint; Olivier Rohr
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-12       Impact factor: 11.205

3.  Inhibition of early response genes prevents changes in global joint metabolomic profiles in mouse post-traumatic osteoarthritis.

Authors:  D R Haudenschild; A K Carlson; D L Zignego; J H N Yik; J K Hilmer; R K June
Journal:  Osteoarthritis Cartilage       Date:  2018-12-18       Impact factor: 6.576

4.  High throughput short interfering RNA (siRNA) screening of the human kinome identifies novel kinases controlling the canonical nuclear factor-κB (NF-κB) activation pathway.

Authors:  Sanjeev Choudhary; Kevin P Rosenblatt; Ling Fang; Bing Tian; Zhao-Hui Wu; Allan R Brasier
Journal:  J Biol Chem       Date:  2011-09-07       Impact factor: 5.157

5.  Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy.

Authors:  Stephen L Abrams; Linda S Steelman; John G Shelton; William Chappell; Jörg Bäsecke; Franca Stivala; Marco Donia; Ferdinando Nicoletti; Massimo Libra; Alberto M Martelli; James A McCubrey
Journal:  Cell Cycle       Date:  2010-05-15       Impact factor: 4.534

6.  In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183.

Authors:  Randy S Schrecengost; Cecelia L Green; Yan Zhuang; Staci N Keller; Ryan A Smith; Lynn W Maines; Charles D Smith
Journal:  J Pharmacol Exp Ther       Date:  2018-02-06       Impact factor: 4.030

Review 7.  Identification of innate immune response endotypes in asthma: implications for personalized medicine.

Authors:  Allan R Brasier
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

8.  Activation of P-TEFb at sites of dual HIV/TB infection, and inhibition of MTB-induced HIV transcriptional activation by the inhibitor of CDK9, Indirubin-3'-monoxime.

Authors:  Zahra Toossi; Mianda Wu; Christina S Hirsch; Harriet Mayanja-Kizza; Joy Baseke; Htin Aung; David H Canaday; Koh Fujinaga
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-06       Impact factor: 2.205

9.  RelA Ser276 phosphorylation-coupled Lys310 acetylation controls transcriptional elongation of inflammatory cytokines in respiratory syncytial virus infection.

Authors:  Allan R Brasier; B Tian; M Jamaluddin; Mridul K Kalita; Roberto P Garofalo; Muping Lu
Journal:  J Virol       Date:  2011-09-07       Impact factor: 5.103

10.  Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2.

Authors:  Aaron E Hoffman; Tongzhang Zheng; Richard G Stevens; Yue Ba; Yawei Zhang; Derek Leaderer; Chunhui Yi; Theodore R Holford; Yong Zhu
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.